News Archive Take a trip down Theragnostics memory lane with our news archive below Developing radionuclide PARP inhibitors – MedNous ArticleNovember 19, 2020Theragnostics Holding 1-2-1 Meetings at Jefferies 2020 Virtual London Healthcare ConferenceNovember 10, 2020Summit Biomedical Imaging Signs Agreement with Theragnostics Enabling the Development of Novel Fluorescence-Based Cancer DiagnosticsSeptember 9, 2020Theragnostics Collaborate on £6 million MITHRAS Research ProgrammeJune 2, 2020Dr Greg Mullen, Theragnostics CEO Gains Leadership RecognitionMay 7, 2020Theragnostics attending PSMA Masterclass – LondonMarch 5, 2020Theragnostics attending JPM in San FranciscoJanuary 13, 2020Theragnostics Expands Team with Significant AppointmentsJanuary 10, 2020Theragnostics strengthens leadership team with two key appointmentsNovember 13, 2019GE Healthcare and Theragnostics announce global commercial partnership for late stage PSMA diagnostic for prostate cancerOctober 9, 2019Theragnostics Reports Positive Clinical Trial Results from Prostate Cancer StudyOctober 2, 2019Theragnostics will be @ EANM ’19 – Booth #4September 30, 2019Theragnostics will be at the Theranostics World Congress 2019February 20, 2019We are hiring! – Chief Medical Officer (application window now closed)February 19, 2019Nick Stevens appointed Executive Chairman Theragnostics LtdJanuary 25, 2019Theragnostics will be at EANM ’18September 10, 2018THERAGNOSTICS SIGNS AGREEMENT WITH ASTRAZENECASeptember 5, 2019Theragnostics CEO Greg Mullen presenting at Targeted Radiopharmaceuticals SummitJune 12, 2019Is it June already?! – Meet us @ SNMMI ’19June 6, 2019Theragnostics Ltd Expands Oncology Portfolio with Licensing of radioPARP InhibitorFebruary 28, 2019Developing radionuclide PARP inhibitors – MedNous ArticleNovember 19, 2020Theragnostics Holding 1-2-1 Meetings at Jefferies 2020 Virtual London Healthcare ConferenceNovember 10, 2020Summit Biomedical Imaging Signs Agreement with Theragnostics Enabling the Development of Novel Fluorescence-Based Cancer DiagnosticsSeptember 9, 2020Theragnostics Collaborate on £6 million MITHRAS Research ProgrammeJune 2, 2020Dr Greg Mullen, Theragnostics CEO Gains Leadership RecognitionMay 7, 2020Theragnostics attending PSMA Masterclass – LondonMarch 5, 2020Theragnostics attending JPM in San FranciscoJanuary 13, 2020Theragnostics Expands Team with Significant AppointmentsJanuary 10, 2020Developing radionuclide PARP inhibitors – MedNous ArticleNovember 19, 2020Theragnostics Holding 1-2-1 Meetings at Jefferies 2020 Virtual London Healthcare ConferenceNovember 10, 2020Summit Biomedical Imaging Signs Agreement with Theragnostics Enabling the Development of Novel Fluorescence-Based Cancer DiagnosticsSeptember 9, 2020Theragnostics Collaborate on £6 million MITHRAS Research ProgrammeJune 2, 2020Dr Greg Mullen, Theragnostics CEO Gains Leadership RecognitionMay 7, 2020Theragnostics attending PSMA Masterclass – LondonMarch 5, 2020Theragnostics attending JPM in San FranciscoJanuary 13, 2020Theragnostics Expands Team with Significant AppointmentsJanuary 10, 2020
Theragnostics Holding 1-2-1 Meetings at Jefferies 2020 Virtual London Healthcare ConferenceNovember 10, 2020
Summit Biomedical Imaging Signs Agreement with Theragnostics Enabling the Development of Novel Fluorescence-Based Cancer DiagnosticsSeptember 9, 2020
GE Healthcare and Theragnostics announce global commercial partnership for late stage PSMA diagnostic for prostate cancerOctober 9, 2019
Theragnostics Holding 1-2-1 Meetings at Jefferies 2020 Virtual London Healthcare ConferenceNovember 10, 2020
Summit Biomedical Imaging Signs Agreement with Theragnostics Enabling the Development of Novel Fluorescence-Based Cancer DiagnosticsSeptember 9, 2020
Theragnostics Holding 1-2-1 Meetings at Jefferies 2020 Virtual London Healthcare ConferenceNovember 10, 2020
Summit Biomedical Imaging Signs Agreement with Theragnostics Enabling the Development of Novel Fluorescence-Based Cancer DiagnosticsSeptember 9, 2020
